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TBLBAbstract Sarcoidosis is a chronic systemic granulomatous disorder of unknown etiology, which
most commonly presents with bilateral hilar adenopathy and pulmonary infiltrates. Fiberoptic
bronchoscopic procedures are the most important tools for the diagnosis sarcoidosis.
Purpose: A retrospective study was done to evaluate the efficacy and safety of bronchoscopic
diagnostic procedures in pulmonary sarcoidosis.
Patients and methods: This retrospective study was done by reviewing the records of the bron-
choscopic procedures and pathological reports performed between May 2012 and September
2015 to assess the diagnostic yield, and safety and bronchoscopic procedures (TBNA, EBB and
TBLB) of cases of sarcoidosis done in the bronchoscopy unit of Chest Department, Mansoura
University. We included adult patients with mediastinal lymphadenopathy with or without diffuse
pulmonary infiltrate with suspected sarcoidosis with indicated fiberoptic bronchoscopy and
excluded patients unfit for FOB with uncorrectable bleeding diathesis, patients with uncontrolled
cardiac comorbidities and respiratory failure. The diagnostic yield and complications were the end-
points of our study.
Results: Regarding the diagnostic yield, TBNA showed the diagnosis of 4 out of 8 patients
(50%) in stage I and 3 out of 5 patients (60%) in stage II. In all the studied cases, TBNA showed
the diagnosis of 7 out of 13 patients (53.8%). EBB showed the diagnosis of 2 out of 2 (100%) in
stage I, 1 out of 2 patients (50%) in stage II and 1 out of 2 patients (50%) in stage III. In all the
studied cases, EBB showed the diagnosis of 4 out of 6 patients (66.7%). TBLB∕EBB showed the
diagnosis of 6 out of 12 patients (50%) in stage II and diagnosis of 4 out of 7 patients (57%) in
stage III. In all the studied cases, TBLB∕EBB showed the diagnosis of 10 out of 19 patients
(52.6%). Pneumothorax developed only in 4 patients (12%), hemoptysis developed in 5 patients
(16%) and no procedure related mortality.
Conclusion: The bronchoscopic diagnostic procedures (TBNA, EBB and TBLB) are effective
and safe in the diagnosis of pulmonary sarcoidosis.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Sarcoidosis is a systemic granulomatous disease of unknown
etiology. It is often suspected when a chest X-ray performed
for non-specific symptoms such as dyspnea or chest pain shows
the characteristic findings of bilateral hilar adenopathy with or
without diffuse pulmonary infiltrates [1].
The classification system developed 50 years ago remains in
use even today. In stage I hilar and mediastinal lym-
phadenopathy alone are present. Stage II is defined by
adenopathy plus pulmonary infiltrates, stage III by pulmonary
infiltrates alone and stage IV includes radiographic evidence of
pulmonary fibrosis. More recently stage 0 has been added
when the chest roentgenogram shows none of these abnormal-
ities [2].
Bronchoscopic procedures are most often done for detec-
tion of granulomas because the lung and hilar or mediastinal
lymph nodes are the most affected sites in sarcoidosis [3].
The most commonly used bronchoscopy procedures
include transbronchial lung biopsy (TBLB) for sampling lung
parenchyma, endobronchial biopsy (EBB) for detecting granu-
loma in the airways, and transbronchial needle aspiration
(TBNA) for sampling mediastinal and hilar lymph nodes.
Bronchoalveolar lavage (BAL) helps in the diagnosis and
exclude tuberculosis and fungal infections [4]. Realtime convex
probe endobronchial ultrasound-guided TBNA (EBUS–
TBNA) has been demonstrated to have an excellent yield in
sarcoidosis, due to direct visualization of the lymph nodes
behind the tracheobronchial wall [5].
The diagnostic yield of TBLB ranges from 60% to 97%
depending on the radiographic stage of the disease and the
number of biopsies performed [6]. In radiographic stage I
where the pulmonary parenchyma appears normal on plain
radiograph, the yield is approximately 50% [7]. The number
of biopsies required to maximize diagnostic yield is about 4–
5 [8].
Endobronchial affection is frequent in pulmonary sarcoido-
sis. In the presence of abnormalities of the bronchial mucosa
including nodularity, hyperemia, EBB has been reported to
be diagnostic in over 90% of cases. Even when the mucosa
appears normal, a positive biopsy may be obtained in about
30% of cases. Moreover, the addition of EBB to TBLB
increases overall diagnostic yield [9].
In BAL for sarcoidosis, an increase in lymphocytes can be
found in 90% of patients with sarcoidosis at the time of diag-
nosis. Patients with active disease tend to have higher lympho-
cyte counts than those with inactive sarcoidosis but the range
is wide, and BAL may be normal in 10–15% of patients. In late
or advanced sarcoidosis, neutrophils may also be increased as
well as the mast cells [10].
The aim of this retrospective study was to evaluate the effi-
cacy and safety of bronchoscopic diagnostic procedures of sar-
coidosis of the lung.
Patients and methods
This retrospective study was done by reviewing the records of
the bronchoscopic procedures and pathological reports per-
formed between May 2012 and September 2015 to assess the
diagnostic yield, and safety and bronchoscopic procedures
(TBNA, EBB and TBLB) of cases of sarcoidosis done in thebronchoscopy unit of Chest Department, Mansoura
University.
Written consent was obtained from all the patients before
the procedure. We included adult patients with mediastinal
lymphadenopathy with or without diffuse pulmonary infiltrate
with suspected sarcoidosis with indicated fiberoptic bron-
choscopy and excluded patients unfit for FOB with uncor-
rectable bleeding diathesis, patients with uncontrolled cardiac
comorbidities like intractable arrhythmia and respiratory
failure.
This study included 31 patients 18 males (58.1%) and 13
females (41.9%) with median age 41.77 ± 13.04.
All Patients were subjected to the following: clinical evalu-
ation; (full history taking and clinical examination), laboratory
investigation: (CBC, liver function, kidney function, bleeding
profile, ESR, collagen profile), Spirometry (using Smart PFT
CO with stress on FVC% and FEV1% of the predicted and
FEV1/FVC ratio), chest X-ray and post contrast high resolu-
tion CT chest then FOB.
Fiberoptic bronchoscopic
Fiberoptic bronchoscopy was done in a bronchoscopy room
for diagnosis. FOB (Pentax FB 19 TV, Tokyo, Japan, with
porcelain tip and inner channel diameter of 3.2 mm) was used
after local instillation of 2% lidocaine and IV 5–10 mg midazo-
lam before the procedure. FOB was introduced via oral route.
During bronchoscopy, endobronchial abnormalities (nodu-
larity, hyperemia or broad carina) were observed. BAL was
done and sent for cellular pattern, bacterial and fungal culture
and ZN stain for acid fast bacilli. TBNA was done from sub-
carinal lymph nodes or paratracheal nodes and the sample was
prepared on glass slides and fixed in 95% ethanol and sent for
cytopathological examination. EBB was done to patients with
endobronchial nodular abnormality. TBLB was done to
patients with parenchymal infiltrations and followed by EBB
and the biopsies were prepared in formalin and sent for patho-
logical examination. TBLB was performed from the most
affected lobe on CT chest and it was done without fluoroscopy
using the standard biopsy forceps. Chest X-ray was done after
the procedure by 2 h and 24 h to detect post procedure
complications.
Diagnosis of sarcoidosis
A diagnosis of sarcoidosis was made if the pathological tissue
demonstrating non-caseating granulomas. Cases not diag-
nosed were diagnosed later on by mediastinoscopy, peripheral
lymph node biopsy, skin biopsy or improvement on steroid
therapy after clinical, radiological, culture and suggestive
pathological correlation (epithelioid cells and lymphocytes
but without granuloma formation).
Statistical analysis
Data were analyzed using SPSS (statistical package for social
sciences) version 15. Qualitative data were presented as num-
ber and percent. Comparison between groups was done by
Chi-Square test. Quantitative data were presented as mean
± SD. Student t-test was used to compare between two
groups. P< 0.05 was considered to be statistically significant.
Table 1 Demographic data of the studied cases.







Table 3 Diagnostic yield of sarcoidosis in each procedure in
the studied cases.
Diagnostic procedure N % P
TBNA 7/13 53.8 0.827
EBB 4/6 66.7
TBLB∕EBB 10/19 52.6
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This study included 31 patients, 8 patients in stage I, 14
patients in stage II and 9 patients in stage III.
Table 1 offered knowledge about demographic data of
studied cases that were 18 male (58.1%) and 13 female
(41.9%) with median age 41.77 ± 13.04. 16 patients (51.6%)
were smoker and 15 patients (48.4%) were non smokers.
Table 2 showed that there was lymphocytic predominance
in BAL in stage I (100% of cases) and also in stage II and stage
III but to a lesser extent (85.7% and 66.7% of cases, respec-
tively). Neutrophilic predominance in BAL was more in stage
III than stage II cases (14.3% and 33.3% of cases, respec-
tively). As regards the spirometric lung functions, in stage I
group, 4 patients (50%) were normal and 4 patients (50%)
had obstructive pattern, in stage II group, 8 patients (50%)
had obstructive pattern and 6 patients (42.9%) had restrictive
pattern and in stage III group, 5 patients (55.6%) had obstruc-
tive pattern and 4 patients (44.4%) had restrictive pattern. As
regards the bronchoscopic findings, in stage I, 4 patients (50%)
had broad carina, 2 patients (25%) had normal findings, one
patient (12.5%) had nodular mucosa and one patient
(12.5%) had hyperemic mucosa, in stage II, 7 patients (50%)
had hyperemic mucosa, 4 patients (28.6%) had nodular
mucosa and 3 patients (21.4%) had broad carina, in stageTable 2 BAL cellular pattern, spirometry, bronchoscopic finding
sarcoidosis in the studied cases.
Stage I (n= 8) Stage II (n= 14)
n % n %
BAL
Lymphocytic 8 100 12 8
Neutrophilic 0 0 2 1
Spirometry
Normal 4 50 0 0
Obstructive 4 50 8 5
Restrictive 0 0 6 4
Bronchoscopic findings
Normal 2 25 0 0
Nodular 1 12.5 4 2
Hyperemic 1 12.5 7 5
Broad carina 4 50 3 2
Diagnostic method
TBNA 4/8 50 3/5 6
EBB 2/2 100 1/2 5
TBLB∕EBB 0 0 6/12 5
Total diagnosed 6/8 75 8/14 5III, 5 patients (55.6%) had hyperemic mucosa, 3 patients
(33.3%) had nodular mucosa and one patient (11.1%) had
normal findings.
Regarding the diagnostic yield of each bronchoscopic pro-
cedure, in stage I, TBNA showed the diagnosis of 4 out of 8
patients underwent this procedure (50%) and EBB showed
the diagnosis of 2 out of 2 patients underwent this procedure
(100%), in stage II, TBNA showed the diagnosis of 3 out of
5 patients (60%), EBB showed the diagnosis of 1 out of 2
patients (50%) and TBLB∕EBB showed the diagnosis of 6
out of 12 patients underwent this procedure (50%) and in stage
III, EBB showed the diagnosis of 1 out of 2 patients (50%) and
TBLB∕EBB showed the diagnosis of 4 out of 7 patients under-
went this procedure (57%).
Regarding the diagnostic yield of each bronchoscopic pro-
cedure in all the studied cases, TBNA showed the diagnosis of
7 out of 13 patients underwent this procedure (53.8%). The
lymph node sample was obtained from subcarinal in 6 patients
and paratracheal in one patient, and EBB showed the diagno-
sis of 4 out of 6 patients underwent this procedure (66.7%) and
TBLB∕EBB showed the diagnosis of 10 out of 19 patients
underwent this procedure (52.6%). We found that some
patients were diagnosed by more than one procedure. As
shown in Table 3.
19 patients out of 31 patients (61.3%) were diagnosed
pathologically by bronchoscopic procedures and the remaining
cases, 2 cases by mediastinoscopy, one patient by open biopsy,s and the diagnostic yield of each procedure in each stage of
Stage III (n= 9) v2 P
n %
5.7 6 66.7 3.543 0.170
4.3 3 33.3
0 0 15.031 0.005
7.1 5 55.6
2.9 4 44.4




0 0 0 0.124 0.725
0 1/2 50 1.500 0.472
0 4/7 57.1 0.090 0.764
7 5/9 56







n % n % n %
Pneumothorax 1 7.7 0 0 3 15.8
Hemoptysis 2 15.4 1 16.7 2 10.5
476 A.A. Hewidy, A.M. Shebl4 cases by peripheral lymph node biopsy, one patient by skin
biopsy and 4 patients improved on empirical steroid therapy.
Table 4 shows that pneumothorax developed only in 4
patients (12%), one patient with TBNA and 3 patients with
TBLB, only one patients was managed by intercostal tube
drainage and the others spontaneously resolved. Hemoptysis
developed in 5 patients (16%), 2 patients (15.4%) with TBNA,
one patient with EBB and 2 patients with TBLB and all were
managed by only haemostatics. There was no procedure
related mortality (Fig. 1).
Discussion
The diagnosis of sarcoidosis is based on a compatible clinical
and radiological pattern, histological demonstration of non-
caseating granulomas, and exclusion of other diseases with aA
C
Figure 1 Demonstrating non caseating granuloma of sarcoidosis. (
(H&E 400). (B) Sarcoid granuloma, giant cell with asteroid body (H&similar histological, clinical picture or radiological pattern.
An accurate diagnosis requires a multimodality approach that
combines clinical, radiological, and pathological evaluations
[11].
Computed tomography (CT) of the chest is the important
radiological diagnosis of sarcoidosis as it provides visualiza-
tion of the enlarged mediastinal lymph nodes, and of the
changes in the lung parenchyma. In many cases, clinical and
radiological features are the basis for the diagnosis and further
treatment. Hilar or mediastinal lymphadenopathy is present
on CT in 47–94% of patients with sarcoidosis, irrespective of
the radiographic staging [12].
However, in case of suspected sarcoidosis, biopsy specimen
should be obtained to confirm the diagnosis and to exclude the
malignant disease, tuberculosis and histoplasma infection.
Therefore, tissue confirmation is crucial in patients with suspi-
cious sarcoidosis [13].
Biopsy confirmation from one organ is sufficient if compat-
ible clinical, laboratory, or radiologic findings are consistent
with the diagnosis and alternative diagnoses have been
excluded. Positive biopsy material from more than one organ
system may be necessary when sarcoidosis presents in an atyp-
ical presentation. The choice of biopsy site should be guided by
the least invasive and appropriate procedure to yield a diag-
nostic material [14].B
A) Sarcoid granuloma, giant cell with calcified Schaumann body
E 400). (C) Sarcoid granuloma (H&E 100).
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abnormal mediastinal lymph nodes. When less invasive
modalities are inconclusive in suspected sarcoidosis, confirma-
tion using one of several surgical options may be necessary.
For mediastinal lymph adenopathy of diverse etiologies,
mediastinoscopy is diagnostic in 82–97% of reported cases
[15].
The aim of this retrospective study was to evaluate the effi-
cacy and safety of bronchoscopic diagnostic procedures of sar-
coidosis done in the bronchoscopy unit of Chest Department,
Mansoura University during the period from May 2012 to
September 2015.
In our study there was lymphocytic predominance in BAL
in stage I (100% of cases) and also in stage II and stage III but
to a lesser extent (85.7% and 66.7% of cases, respectively).
Neutrophilic predominance in BAL was more in stage III than
stage II cases (14.3% and 33.3% of cases, respectively). These
results showed that neutrophils increase as the stage of the dis-
ease was more progressive. Patients with active disease tend to
have higher lymphocyte counts than those with inactive sar-
coidosis but the range is wide, and BAL may be normal in
10–15% of patients. In late or advanced sarcoidosis, neu-
trophils may also be increased as well as the mast cells [10].
As regards the spirometric lung functions, in stage I group,
4 patients (50%) were normal and 4 patients (50%) had
obstructive pattern, in stage II group, 8 patients (50%) had
obstructive pattern and 6 patients (42.9%) had restrictive pat-
tern and in stage III group, 5 patients (55.6%) had obstructive
pattern and 4 patients (44.4%) had restrictive pattern. Our
results were comparable to the study done by Goyal et al.
[16] in which spirometry was normal in 86 patients (56.9%),
restrictive in 42 patients (27.9%) and obstructive in 23 patients
(15.2%).
As regards the bronchoscopic findings, in stage I, 4 patients
(50%) had broad carina, 2 patients (25%) had normal find-
ings, one patient (12.5%) had nodular mucosa and one patient
(12.5%) had hyperemic mucosa, in stage II, 7 patients (50%)
had hyperemic mucosa, 4 patients (28.6%) had nodular
mucosa and 3 patients (21.4%) had broad carina, and in stage
III, 5 patients (55.6%) had hyperemic mucosa, 3 patients
(33.3%) had nodular mucosa and one patient (11.1%) had
normal findings. Our results were more than those described
by Goyal et al. [16] who reported that on bronchoscopy, muco-
sal abnormalities (mucosal granularity, nodularity, edema, or
hyperemia) were seen in 29 (19.2%) patients. This may be
due to different numbers of cases and different stages between
both studies.
Regarding the diagnostic yield of each bronchoscopic pro-
cedure, TBNA showed the diagnosis of 4 out of 8 patients
(50%) in stage I and 3 out of 5 patients (60%) in stage II. In
all the studied cases, TBNA showed the diagnosis of 7 out of
13 patients underwent this procedure (53.8%). This was com-
parable to a study done by Ozbudak et al. [17] who reported
the diagnosis of chronic granulomatous inflammation was
made in 4 of 7 cases where a single lymph node, 25 of 28 cases
where two lymph nodes and 2 of 3 cases where three lymph
nodes were sampled. But in our study we had single lymph
node biopsy so the diagnostic yield was more in this study in
patients with more than one lymph node biopsy.
EBB showed the diagnosis of 2 out of 2 (100%) in stage I, 1
out of 2 patients (50%) in stage II and 1 out of 2 patients
(50%) in stage III. In all the studied cases, EBB showed thediagnosis of 4 out of 6 patients underwent this procedure
(66.7%). TBLB∕EBB showed the diagnosis of 6 out of 12
patients (50%) in stage II and diagnosis of 4 out of 7 patients
(57%) in stage III. In all the studied cases, TBLB∕EBB showed
the diagnosis of 10 out of 19 patients underwent this procedure
(52.6%). In a study done by Dziedzic et al. [13] the sensitivity
of TBLB and EBB in all patients (stage I and II) reached
43.9% and 29.7%, respectively, the relatively low diagnostic
yield of EBB can be explained by the small group of patients
with airway involvement in their study. The diagnostic yield
of TBLB for sarcoidosis by showing non-caseating epithelioid
cell granuloma is 37% (stage I: 31%; stage II: 50%) [18]. EBB
has a lower yield than TBLB that varies between 20% and
62%. Visible mucosal abnormalities give higher yields of 54–
91% although 20%–40% of normal-appearing mucosa can
also show granuloma on histology [19]. Visible mucosal abnor-
malities give higher yields of 54–91%, although 20–% of
normal-appearing mucosa can also show granuloma on histol-
ogy [19]. The presence of radiologic stage 2 or 3 and the num-
ber of biopsies obtained have been associated with higher
yields of TBLB Visible mucosal [16].
As regards the post procedural complications, pneumotho-
rax developed only in 4 patients, one patient with TBNA and 3
patients with TBLB, only one patient was managed by inter-
costal tube drainage and the others spontaneously resolved.
Hemoptysis developed in 5 patients, 2 patients with TBNA,
one patient with EBB and 2 patients with TBLB and all man-
aged by only hemostatics. There was no procedure related
mortality. This was comparable to the results of Goyal et al.
[16] who reported that one patient developed pneumothorax
after bronchoscopy which was managed with simple needle
aspiration and no major hemorrhage. Our results were less
than reported by a study of 540 patients in which the compli-
cation rate was 0.18% in those who did not undergo TBLB,
compared to 2.0% in those who underwent TBLB [20]. In
another study, the risk of pneumothorax following TBLB
was 1.8% when fluoroscopy was used, and increased to 2.3–
2.9% without fluoroscopy [21] and this can be explained by
a small number of cases in our study, different stages of stud-
ied cases.Conclusion
The bronchoscopic diagnostic procedures (TBNA, EBB and
TBLB) are effective and safe in the diagnosis of sarcoidosis
and reduce the need for other more invasive procedures.Conﬂict of interest
There is no conflict of interests in this study.
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